Pelareorep

Biotech stocks like Rapt Therapeutics, Sol-Gel Technologies, and Puma Biotechnology are seeing significant search interest surges, highlighting their focus on innovative treatments for diseases ranging from cancer to skin conditions.

The breast cancer drugs market is rapidly expanding, driven by targeted therapies for HER2-positive cancers. The global market, valued at USD 32.93 billion in 2023, is projected to reach USD 78.61 billion by 2033. North America leads with a 38.61% revenue share. Key players include Oncolytics Biotech, GSK, AstraZeneca, AbbVie, and Cardiff Oncology.

Oncolytics Biotech reports promising BRACELET-1 results in HR+/HER2- metastatic breast cancer, setting stage for potential registration-enabling study and accelerated approval. The company also highlights advancements in its gastrointestinal cancer pipeline, with collaborations for pancreatic cancer studies. Anticipated milestones include finalizing protocols and safety data in 2025.

Oncolytics Biotech collaborates with GCAR and PanCAN on pancreatic cancer studies, advancing pelareorep treatments. Enrollment expansion in anal cancer offers new registrational study opportunities. Upcoming milestones include finalizing protocols and presenting data at ASCO GI 2025. The company also plans investor meetings during the J.P. Morgan Healthcare Conference.

The global pancreatic cancer market is projected to grow from USD 3.1 billion in 2023 to USD 11.5 billion by 2033, driven by advancements in precision medicine, novel chemotherapy combinations, and emerging immunotherapies. Key trends include targeting KRAS mutations, reevaluating growth factors like G-CSF, and innovations in diagnostic technologies and gene-editing. Despite challenges, ongoing research and drug approvals offer hope for improved patient outcomes.

DSMB recommends continuing GOBLET study cohort 5 after safety review. Cohort 5 investigates pelareorep with mFOLFIRINOX, with/without atezolizumab, in newly diagnosed PDAC. Full trial updates expected in 2025.

Oncolytics Biotech reports DSMB recommendation for continued enrollment in GOBLET study Cohort 5, assessing pelareorep with modified FOLFIRINOX and atezolizumab for pancreatic ductal adenocarcinoma, pending PEI approval. Safety data expected in H1 2025, with initial efficacy results in H2.

Oncolytics Biotech Inc. announces key progress and upcoming studies for breast and pancreatic cancer treatments, preparing for FDA accelerated approval. The company's lead intravenously administered immunotherapy, pelareorep, shows promising efficacy in ongoing trials, with plans to initiate a clinical trial to support accelerated FDA approval in 2025.